ATE471945T1 - Als medikament geeignete lösliche varianten des gp130-moleküls - Google Patents
Als medikament geeignete lösliche varianten des gp130-molekülsInfo
- Publication number
- ATE471945T1 ATE471945T1 AT06841152T AT06841152T ATE471945T1 AT E471945 T1 ATE471945 T1 AT E471945T1 AT 06841152 T AT06841152 T AT 06841152T AT 06841152 T AT06841152 T AT 06841152T AT E471945 T1 ATE471945 T1 AT E471945T1
- Authority
- AT
- Austria
- Prior art keywords
- soluble
- medication
- molecule used
- soluble variants
- polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Neurology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05028420A EP1801121A1 (de) | 2005-12-23 | 2005-12-23 | Lösliche Varianten des Moleküls gp130 nützlich als Arzneimittel |
PCT/EP2006/012515 WO2007071449A1 (en) | 2005-12-23 | 2006-12-22 | Soluble gp130 molecule variants useful as a medicament |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE471945T1 true ATE471945T1 (de) | 2010-07-15 |
Family
ID=36233865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06841152T ATE471945T1 (de) | 2005-12-23 | 2006-12-22 | Als medikament geeignete lösliche varianten des gp130-moleküls |
Country Status (9)
Country | Link |
---|---|
US (1) | US7851182B2 (de) |
EP (2) | EP1801121A1 (de) |
JP (1) | JP5390191B2 (de) |
AT (1) | ATE471945T1 (de) |
AU (1) | AU2006328909A1 (de) |
CA (1) | CA2633213A1 (de) |
DE (1) | DE602006015103D1 (de) |
ES (1) | ES2347694T3 (de) |
WO (1) | WO2007071449A1 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602006016765D1 (de) | 2006-06-30 | 2010-10-21 | Conaris Res Inst Ag | Verbesserte sgp 130Fc Dimere |
JP5424330B2 (ja) * | 2007-07-26 | 2014-02-26 | 国立大学法人大阪大学 | インターロイキン6受容体阻害剤を有効成分とする眼炎症疾患治療剤 |
EP2050759A1 (de) * | 2007-10-19 | 2009-04-22 | CONARIS research institute AG | Lösliche gp-130-Muteine mit verbesserter Bindungsaktivität |
MA41116A (fr) | 2014-12-01 | 2017-10-10 | Ferring Bv | Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif |
MA41114B1 (fr) | 2014-12-01 | 2021-06-30 | Ferring Bv | Administration d'un inhibiteur de signalisation de trans-signalisation par il-6 sélectif |
WO2017106244A1 (en) * | 2015-12-14 | 2017-06-22 | The Trustees Of The University Of Pennsylvania | Compositions and methods for regulatable antibody expression |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994012520A1 (en) * | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
AU778998B2 (en) * | 1998-09-22 | 2004-12-23 | University Of Maryland At Baltimore | Cystine knot growth factor mutants |
CN1341121A (zh) * | 1999-01-07 | 2002-03-20 | 利思进药品公司 | 作为Fc融和蛋白之抗肥胖蛋白质的表达和外运 |
EP1148065B1 (de) * | 2000-04-21 | 2008-01-02 | CONARIS research institute AG | Fusionsproteine, die zwei lösliche gp130 Moleküle enthalten |
ATE384783T1 (de) * | 2001-10-19 | 2008-02-15 | Zymogenetics Inc | Dimerisierter wachstumsfaktor sowie materialien und verfahren zu seiner herstellung |
EP1491554A1 (de) * | 2003-06-23 | 2004-12-29 | CONARIS research institute AG | PEGlierte lösliche gp130-Dimeren geignet als Medikament |
JP2008504012A (ja) * | 2004-01-28 | 2008-02-14 | シントニックス・ファーマシューティカルズ・インコーポレーテッド | 不妊治療のためのへテロ二量体卵胞刺激ホルモン−Fc(FSH−Fc)融合タンパク質 |
-
2005
- 2005-12-23 EP EP05028420A patent/EP1801121A1/de not_active Withdrawn
-
2006
- 2006-12-22 AU AU2006328909A patent/AU2006328909A1/en not_active Abandoned
- 2006-12-22 DE DE602006015103T patent/DE602006015103D1/de active Active
- 2006-12-22 US US12/158,285 patent/US7851182B2/en active Active
- 2006-12-22 AT AT06841152T patent/ATE471945T1/de not_active IP Right Cessation
- 2006-12-22 WO PCT/EP2006/012515 patent/WO2007071449A1/en active Application Filing
- 2006-12-22 ES ES06841152T patent/ES2347694T3/es active Active
- 2006-12-22 JP JP2008546287A patent/JP5390191B2/ja active Active
- 2006-12-22 CA CA002633213A patent/CA2633213A1/en not_active Abandoned
- 2006-12-22 EP EP06841152A patent/EP1994053B1/de active Active
Also Published As
Publication number | Publication date |
---|---|
DE602006015103D1 (de) | 2010-08-05 |
EP1994053B1 (de) | 2010-06-23 |
EP1994053A1 (de) | 2008-11-26 |
WO2007071449A1 (en) | 2007-06-28 |
EP1801121A1 (de) | 2007-06-27 |
CA2633213A1 (en) | 2007-06-28 |
JP2009520480A (ja) | 2009-05-28 |
JP5390191B2 (ja) | 2014-01-15 |
AU2006328909A1 (en) | 2007-06-28 |
US20090227499A1 (en) | 2009-09-10 |
US7851182B2 (en) | 2010-12-14 |
ES2347694T3 (es) | 2010-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE471945T1 (de) | Als medikament geeignete lösliche varianten des gp130-moleküls | |
Bai et al. | Improving the oral efficacy of recombinant granulocyte colony-stimulating factor and transferrin fusion protein by spacer optimization | |
Andreotti | Native state proline isomerization: an intrinsic molecular switch | |
Van Goethem et al. | Structure–activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal? | |
EA200801166A1 (ru) | Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа | |
TW200730539A (en) | Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1 | |
Hovanessian | Midkine, a cytokine that inhibits HIV infection by binding to the cell surface expressed nucleolin | |
MEP53308A (en) | Novel peptides that bind to the erythropoietin receptor | |
JP2008500025A5 (de) | ||
ATE473759T1 (de) | Bifunktionelle moleküle sowie darauf basierende therapien. | |
ATE548381T1 (de) | Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus | |
Cohen et al. | Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an azabicyclooctane scaffold | |
ATE457728T1 (de) | Kristallstruktur des aurora-2 proteins und dessen bindungstaschen | |
UA98295C2 (ru) | Опухолево-ассоциированный пептид, который неспецифически связывается с молекулами ii класса лейкоцитарного антигена человека (hla) | |
JP2012522529A5 (de) | ||
Peng et al. | Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at μ, δ, and κ opioid receptors | |
Suzuki et al. | Syndecan binding sites in the laminin α1 chain G domain | |
RU2014143639A (ru) | Регулируемые протеазой антитела | |
IL187321A (en) | Molecules that have a specific link to a surrogate cell that encode monoclonal antibodies capable of neutralizing viruses, medicinal preparations containing them, and their uses in drug preparation | |
Inokuchi et al. | Potent CXCR4 antagonists containing amidine type peptide bond isosteres | |
Cai et al. | Metal-assisted assembly and stabilization of collagen-like triple helices | |
Voltà-Durán et al. | Controlling self-assembling and tumor cell-targeting of protein-only nanoparticles through modular protein engineering | |
ATE491044T1 (de) | Gene und polypeptide in verbindung mit brustkrebserkrankungen | |
Fox et al. | Examination of glycosaminoglycan binding sites on the XCL1 dimer | |
BRPI0407031A (pt) | Composições e métodos para tratamento de câncer empregando igsf9 e liv-1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |